Buy or sell Synergy Pharmaceuticals stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Synergy Pharmaceuticals Stock
Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions.
About Synergy Pharmaceuticals Stock
Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.
President & CEO
Gary S. Jacob
Patrick H. Griffin
Synergy Pharmaceuticals Moves Forward on Path Toward Sale
Wall Streets Journal - Dec, 14 2018
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase